Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Lazertinib: breaking the mold of third-generation EGFR inhibitors

RSC Medicinal Chemistry(2025)10.1039/d4md00800fSource: DataRank Database

Lazertinib: breaking the mold of third-generation EGFR inhibitors is a research paper published in RSC Medicinal Chemistry (2025). On theSindex it has a DataRank of 0. It has been cited 16 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access16 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 13.05)OA: hybridTopics (14)IDs (PubMed, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

David E. Heppner ORCID,Kishan B. Patel

Live enrichment

PubMed:39867588 OpenAlex:https://openalex.org/W4406124307

National Center for Advancing Translational Sciences

Grant: UL1TR001412

National Institute of General Medical Sciences

Grant: R35GM155353

National Institutes of Health

Grant: 3UL1TR001412-08S3

Buffalo Clinical and Translational Research Center

National Institutes of Health

Grant: 1R35GM155353-01

Improving Drug Development Through Studies of Protein Kinase Inhibitors

FWCI

13.05

Citation Percentile

1.0%

Citation Trend

2025

2026

hybridLicense: cc-by-nc

journalhttps://pubs.rsc.org/en/content/articlepdf/2025/md/d4md00800f

publisherhttps://pubs.rsc.org/en/content/articlepdf/2025/md/d4md00800f

publisherhttp://pubs.rsc.org/en/content/articlepdf/2025/MD/D4MD00800F

journalhttps://doi.org/10.1039/d4md00800f

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39867588

Fields of Study

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchChronic Myeloid Leukemia Treatments03 medical and health sciences0302 clinical medicine

Keywords

MoldEGFR inhibitorsChemistryMedicineMaterials scienceEpidermal growth factor receptorCancerInternal medicineComposite material